KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Research & Development (2016 - 2025)

Historic Research & Development for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $31.9 million.

  • Halozyme Therapeutics' Research & Development rose 5604.42% to $31.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $81.5 million, marking a year-over-year increase of 308.93%. This contributed to the annual value of $81.5 million for FY2025, which is 308.93% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Research & Development of $31.9 million as of Q4 2025, which was up 5604.42% from $17.3 million recorded in Q3 2025.
  • Halozyme Therapeutics' Research & Development's 5-year high stood at $31.9 million during Q4 2025, with a 5-year trough of $8.1 million in Q2 2021.
  • Moreover, its 5-year median value for Research & Development was $17.4 million (2023), whereas its average is $17.0 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 12324.89% in 2022, then crashed by 2256.29% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Research & Development stood at $10.1 million in 2021, then surged by 123.25% to $22.6 million in 2022, then decreased by 5.45% to $21.3 million in 2023, then decreased by 4.19% to $20.4 million in 2024, then soared by 56.04% to $31.9 million in 2025.
  • Its last three reported values are $31.9 million in Q4 2025, $17.3 million for Q3 2025, and $17.5 million during Q2 2025.